NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report) saw a significant decrease in short interest in January. As of January 30th, there was short interest totaling 41 shares, a decrease of 83.2% from the January 15th total of 244 shares. Based on an average daily volume of 459 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 459 shares, the days-to-cover ratio is currently 0.1 days.
NewAmsterdam Pharma Stock Performance
Shares of NASDAQ:NAMSW traded up $1.95 on Tuesday, reaching $22.26. The company’s stock had a trading volume of 3,326 shares, compared to its average volume of 1,002. The company has a 50-day simple moving average of $23.15 and a 200 day simple moving average of $20.86. NewAmsterdam Pharma has a 52-week low of $5.45 and a 52-week high of $29.99.
Hedge Funds Weigh In On NewAmsterdam Pharma
An institutional investor recently raised its position in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC lifted its position in NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) by 1.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 245,000 shares of the company’s stock after purchasing an additional 3,043 shares during the quarter. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $1,960,000 as of its most recent SEC filing.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.
The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.
Featured Stories
- Five stocks we like better than NewAmsterdam Pharma
- They just tried to kill gold
- What a Former CIA Agent Knows About the Coming Collapse
- Nvidia CEO Issues Bold Tesla Call
- How to collect $500-$800 weekly (BlackRock’s system)
- New gold price target
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
